Management of Stage 2 Hypertension with Losartan

Initial Combination Therapy

The American College of Cardiology recommends adding either a calcium channel blocker (amlodipine 5-10mg daily) or a thiazide diuretic (chlorthalidone 12.5-25mg or hydrochlorothiazide 25mg daily) to losartan for stage 2 hypertension 1, 2, 3
The combination of ARB + CCB is a preferred two-drug combination across all major international guidelines (JNC 8, ESH/ESC, ACC/AHA, NICE, Taiwan, China) 6, 7
Research demonstrates that ARB/CCB combination therapy (losartan/amlodipine) reduced blood pressure more effectively than maximal doses of ARB with hydrochlorothiazide (losartan/HCTZ) in stage 2 hypertensive patients 1, 2, 3

For Black patients, the combination of a thiazide diuretic with losartan may be more effective than adding a CCB, as thiazide diuretics and calcium-channel blockers are recommended as first-line agents in Black patients 2, 3
Beta-blockers and renin-angiotensin system inhibitors are less effective at lowering blood pressure in Black patients 2, 3

The American College of Cardiology recommends initiating two antihypertensive agents from different classes simultaneously for patients with stage 2 hypertension and blood pressure >20/10 mmHg above target (≥160/100 mmHg) 1, 2, 3, 8
The 2017 ACC/AHA guidelines explicitly recommend starting two first-line agents simultaneously (either as separate agents or in a fixed-dose combination) in adults with stage 2 hypertension 1, 8

Check serum potassium and creatinine 2-4 weeks after initiating or adding therapy, especially when using ARBs or diuretics 1, 4, 5
Reassess blood pressure within 1 month after adding the second agent for stage 2 hypertension 1, 2
Target blood pressure is <130/80 mmHg according to 2017 ACC/AHA guidelines 1, 2, 3

Add a third agent from the remaining class to achieve guideline-recommended triple therapy: ARB + CCB + thiazide diuretic 6, 7, 4
All major guidelines (JNC 8, ESH/ESC, NICE, Taiwan, China) specify CCB + thiazide + ARB as the standard three-drug combination 6, 7

Never combine losartan with an ACE inhibitor, as this increases adverse events (hyperkalemia, acute kidney injury) without additional cardiovascular benefit 1, 4, 5
Do not add a beta-blocker as the second agent unless there are compelling indications such as angina, post-myocardial infarction, heart failure with reduced ejection fraction, or need for heart rate control 4, 9